Initiation of Clinical Trials, Completed Acquisitions, Financial Results, and Earnings Release Schedules - Analyst Notes on Cell

Initiation of Clinical Trials, Completed Acquisitions, Financial Results, and
  Earnings Release Schedules - Analyst Notes on Cell Therapeutics, Intrexon,
                 Chimerix, Receptos, and Revance Therapeutics

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, March 18, 2014

NEW YORK, March 18, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Cell
Therapeutics, Inc. (NASDAQ: CTIC), Intrexon Corporation (NYSE: XON), Chimerix,
Inc. (NASDAQ: CMRX), Receptos, Inc. (NASDAQ: RCPT), andRevance Therapeutics,
Inc. (NASDAQ: RVNC). Private wealth members receive these notes ahead of
publication. To reserve complementary membership, limited openings are
available at: http://www.AnalystsReview.com/register

CellTherapeutics,Inc.AnalystNotes

On March 3, 2014, Cell Therapeutics, Inc. (CTI) announced the initiation of a
Phase 3 clinical trial, PERSIST-2, evaluating pacritinib. Pacritinib is a
novel investigational JAK2/FLT3 inhibitor, in patients with myelofibrosis
whose platelet counts are less than or equal to 100,000 per microliter (uL).
"With the initiation of the PERSIST-2 trial, we believe that the registration
program for pacritinib is on track for a potential NDA submission in the
latter part of 2015," said James A. Bianco, MD, President and CEO of CTI. "We
have seen meaningful clinical benefits and good tolerability with pacritinib
in myelofibrosis patients in Phase 2 trials without apparent drug-related
thrombocytopenia or anemia. As such, we have had strong interest in site
participation for this trial and will work diligently to activate these sites
over the next several months." The trial is expected to enroll up to 300
patients in North America, Europe, Australia and New Zealand within 12 to 14
months. The full analyst notes on Cell Therapeutics, Inc. are available to
download free of charge at:

http://www.AnalystsReview.com/03182014/CTIC/report.pdf

IntrexonCorporationAnalystNotes

On March 7, 2014, Intrexon Corp. (Intrexon) announced that it has completed
the acquisition of Medistem, Inc., a pioneer in the development of Endometrial
Regenerative Cells. Under the terms of the agreement, Medistem stockholders
will receive in exchange for each share of Medistem common stock $0.27 in cash
and $1.08 worth of Intrexon common stock, or approximately 0.03920 shares.
This is based on the 20-day volume-weighted average price of Intrexon's common
stock immediately prior to closing, subject to adjustment pursuant to the
terms of the merger agreement. The full analyst notes on Intrexon Corporation
are available to download free of charge at:

http://www.AnalystsReview.com/03182014/XON/report.pdf

Chimerix,Inc.AnalystNotes

On March 7, 2014, Chimerix Inc. (Chimerix) reported its Q4 2013 and full-year
2013 financial results. For the quarter, the Company reported a net loss of
$8.2 million or $0.31 per basic and diluted share,compared to a net loss of
$4.3 million or $3.90 per basic and diluted share in Q4 2012. Revenues totaled
$879,000, compared to $3.6 million in Q4 2012. For full-year 2013, net loss
was $36.4 million or $3.65 per basic and diluted share, compared to net loss
of $4.4 million or $5.75 per basic and diluted share in 2012. Revenues were
$4.4 million, compared to $33.7 million in 2012. The decrease in revenues were
attributable to a decrease in reimbursable expenses associated with Chimerix's
ongoing contract with BARDA in 2013, and the receipt of an upfront license
payment related to Chimerix's collaboration and license arrangement with Merck
in 2012. The full analyst notes on Chimerix, Inc. are available to download
free of charge at:

http://www.AnalystsReview.com/03182014/CMRX/report.pdf

Receptos,Inc.AnalystNotes

On March 5, 2014, Receptos, Inc. (Receptos) reported its Q4 2013 and full-year
2013 (period ended December 31, 2013) financial results. For the quarter, the
Company reported net loss of $15.2 million, or $0.86 per common share,
compared to a net loss of $4.5 million, or $3.08 per common share, in Q4 2012.
Total revenues were $773,000, compared to $3.8 million in Q4 2012. Revenue
during these periods consisted primarily of amortization of up-front fees and
milestone payments, and development funding received from our collaborative
arrangements. Fiscal year 2013 net loss was as $50.4 million, or $4.23 per
common share, compared to a net loss of $17.7 million, or $13.73 per common
share, in 2012. Total revenues were $4.6 million compared to $8.6 million in
2012. The full analyst notes on Receptos, Inc. are available to download free
of charge at:

http://www.AnalystsReview.com/03182014/RCPT/report.pdf

RevanceTherapeutics,Inc.AnalystNotes

On March 12, 2014, Revance Therapeutics, Inc. (Revance) announced the schedule
of its earnings release and conference call. The Company will report its Q4
2013 and full-year 2013 financial results on March 26, 2014, Wednesday, after
the close of market. The Company's management will also host a conference call
and live internet webcast on the same day at 1:30 p.m. PT or 4:30 p.m. ET to
discuss the results as well as provide business updates. The webcast will be
available in the Investor Relations section on the Company's website for 30
days following the completion of the call. The full analyst notes on Revance
Therapeutics, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03182014/RVNC/report.pdf

AboutAnalystsReview

We provide our members with a simple and reliable way to leverage our economy
of scale. Most investors do not have time to track all publicly traded
companies, much less perform an in-depth review and analysis of the
complexities contained in each situation. That's where Analysts Review comes
in. We provide a single unified platform for investors' to hear about what
matters. Situation alerts, moving events, and upcoming opportunities.

=============

EDITORNOTES:

  oThis is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
  oInformation in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
  oThis information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
  oIf you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at pubco [at]
    AnalystsReview.com.
  oForanyurgentconcernsorinquiries, please contact us at compliance
    [at] AnalystsReview.com.
  oAre you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to research [at]
    AnalystsReview.com for consideration.

COMPLIANCEPROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Analysts Review. An
outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Analysts Review in this article or
report according to the Procedures outlined by Analysts Review. Analysts
Review is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOTFINANCIALADVICE

Analysts Review makes no warranty, expressed or implied, as to the accuracy or
completeness or fitness for a purpose (investment or otherwise), of the
information provided in this document. This information is not to be construed
as personal financial advice. Readers are encouraged to consult their personal
financial advisor before making any decisions to buy, sell or hold any
securities mentioned herein.

NOWARRANTYORLIABILITYASSUMED

Analysts Review is not responsible for any error which may be occasioned at
the time of printing of this document or any error, mistake or shortcoming. No
liability is accepted by Analysts Review whatsoever for any direct, indirect
or consequential loss arising from the use of this document. Analysts Review
expressly disclaims any fiduciary responsibility or liability for any
consequences, financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1) guarantee the
accuracy, timeliness, completeness or correct sequencing of the information,
or (2) warrant any results from use of the information. The included
information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.AnalystsReview.com

SOURCE Analysts Review

Contact: Contact: Adam Redford, +852-8191-3972
 
Press spacebar to pause and continue. Press esc to stop.